Protein phosphatase 2A: A target for anticancer therapy

The Lancet Oncology

Volumn 14, Issue 6, 2013, Pages

  Perrotti, Danilo ^a   Neviani, Paolo ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,9 DIDEOXYFORSKOLIN; BCR ABL PROTEIN; BETA CATENIN; BORTEZOMIB; CARNOSIC ACID; CHLOROETHYLNITROSOUREA; DASATINIB; FINGOLIMOD; FLT3 LIGAND; FORSKOLIN; IMATINIB; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MYC PROTEIN; NILOTINIB; NUCLEOPORIN 98; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PONATINIB; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 1; SHORT HAIRPIN RNA; SORAFENIB; SPHINGOSINE 1 PHOSPHATE; STAT5 PROTEIN; UNINDEXED DRUG; VORINOSTAT;

BLADDER CARCINOMA; BREAST CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; LIVER CELL CARCINOMA; METHYLATION; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; TREATMENT RESPONSE; WNT SIGNALING PATHWAY;

EID: 84876990097     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70558-2     Document Type: Review

References (98)

1. Tsatsanis C, Spandidos DA The role of oncogenic kinases in human cancer. Int J Mol Med 2000, 5:583-590.
2. Look AT Oncogenic transcription factors in the human acute leukemias. Science 1997, 278:1059-1064.
3. Yip KW, Reed JC Bcl-2 family proteins and cancer. Oncogene 2008, 27:6398-6406.
4. Sherr CJ Principles of tumor suppression. Cell 2004, 116:235-246.
5. Bononi A, Agnoletto C, De Marchi E, et al. Protein kinases and phosphatases in the control of cell fate. Enzyme Res 2011, 2011:329098.
6. Calabretta B, Perrotti D The biology of CML blast crisis. Blood 2004, 103:4010-4022.
7. Perrotti D, Jamieson C, Goldman J, Skorski T Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010, 120:2254-2264.
8. Jabbour E, Parikh SA, Kantarjian H, Cortes J Chronic myeloid leukemia: mechanisms of resistance and treatment. Hematol Oncol Clin North Am 2011, 25:981-995.
9. Trotman LC, Wang X, Alimonti A, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007, 128:141-156.
10. Eichhorn PJ, Creyghton MP, Bernards R Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 2009, 1795:1-15.
11. Perrotti D, Neviani P Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev 2008, 27:159-168.
12. Chen P, Levis M, Brown P, Kim KT, Allebach J, Small D FLT3/ITD mutation signaling includes suppression of SHP-1. J Biol Chem 2005, 280:5361-5369.
13. Samanta AK, Chakraborty SN, Wang Y, et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 2009, 28:1669-1681.
14. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005, 8:355-368.
15. McCright B, Virshup DM Identification of a new family of protein phosphatase 2A regulatory subunits. J Biol Chem 1995, 270:26123-26128.
16. Strack S Overexpression of the protein phosphatase 2A regulatory subunit Bgamma promotes neuronal differentiation by activating the MAP kinase (MAPK) cascade. J Biol Chem 2002, 277:41525-41532.
17. Everett AD, Kamibayashi C, Brautigan DL Transgenic expression of protein phosphatase 2A regulatory subunit B56gamma disrupts distal lung differentiation. Am J Physiol Lung Cell Mol Physiol 2002, 282:1266-1271.
18. Janssens V, Longin S, Goris J PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem Sci 2008, 33:113-121.
19. Shouse GP, Nobumori Y, Panowicz MJ, Liu X ATM-mediated phosphorylation activates the tumor-suppressive function of B56gamma-PP2A. Oncogene 2011, 30:3755-3765.
20. Bockelman C, Koskensalo S, Hagstrom J, Lundin M, Ristimaki A, Haglund C CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther 2012, 13:289-295.
21. Vaarala MH, Vaisanen MR, Ristimaki A CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 2010, 29:136.
22. Wang J, Li W, Li L, Yu X, Jia J, Chen C CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 2011, 33:290-298.
23. Li M, Makkinje A, Damuni Z Molecular identification of I1PP2A, a novel potent heat-stable inhibitor protein of protein phosphatase 2A. Biochemistry 1996, 35:6998-7002.
24. Li M, Makkinje A, Damuni Z The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 1996, 271:11059-11062.
25. Junttila MR, Puustinen P, Niemela M, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007, 130:51-62.
26. McConnell JL, Gomez RJ, McCorvey LR, Law BK, Wadzinski BE Identification of a PP2A-interacting protein that functions as a negative regulator of phosphatase activity in the ATM/ATR signaling pathway. Oncogene 2007, 26:6021-6030.
27. Mochida S, Maslen SL, Skehel M, Hunt T Greatwall phosphorylates an inhibitor of protein phosphatase 2A that is essential for mitosis. Science 2010, 330:1670-1673.
28. Kurimchak A, Grana X PP2A holoenzymes negatively and positively regulate cell cycle progression by dephosphorylating pocket proteins and multiple CDK substrates. Gene 2012, 499:1-7.
29. Wurzenberger C, Gerlich DW Phosphatases: providing safe passage through mitotic exit. Nat Rev Mol Cell Biol 2011, 12:469-482.
30. Lee TY, Lai TY, Lin SC, et al. The B56gamma3 regulatory subunit of protein phosphatase 2A (PP2A) regulates S phase-specific nuclear accumulation of PP2A and the G1 to S transition. J Biol Chem 2010, 285:21567-21580.
31. Ross JA, Cheng H, Nagy ZS, Frost JA, Kirken RA Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3/STAT5 activation. J Biol Chem 2010, 285:3582-3591.
32. Li Y, Yue P, Deng X, et al. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E. Neoplasia 2010, 12:848-855.
33. Janssens V, Rebollo A The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr Mol Med 2012, 12:268-287.
34. Torrent L, Ferrer I PP2A and Alzheimer disease. Curr Alzheimer Res 2012, 9:248-256.
35. Baysal BE, Willett-Brozick JE, Taschner PE, Dauwerse JG, Devilee P, Devlin B A high-resolution integrated map spanning the SDHD gene at 11q23: a 1.1-Mb BAC contig, a partial transcript map and 15 new repeat polymorphisms in a tumour-suppressor region. Eur J Hum Genet 2001, 9:121-129.
36. Chou HC, Chen CH, Lee HS, et al. Alterations of tumour suppressor gene PPP2R1B in hepatocellular carcinoma. Cancer Lett 2007, 253:138-143.
37. Kalla C, Scheuermann MO, Kube I, et al. Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B. Eur J Cancer 2007, 43:1328-1335.
38. Ruediger R, Pham HT, Walter G Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene. Oncogene 2001, 20:1892-1899.
39. Shih IeM, Panuganti PK, Kuo KT, et al. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol 2011, 178:1442-1447.
40. Ruvolo PP, Qui YH, Coombes KR, et al. Low expression of PP2A regulatory subunit B55alpha is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia 2011, 25:1711-1717.
41. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
42. Roberts KG, Smith AM, McDougall F, et al. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res 2010, 70:5438-5447.
43. Ito A, Kataoka TR, Watanabe M, et al. A truncated isoform of the PP2A B56 subunit promotes cell motility through paxillin phosphorylation. Embo J 2000, 19:562-571.
44. Cristobal I, Garcia-Orti L, Cirauqui C, et al. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 2012, 97:543-550.
45. Adachi Y, Pavlakis GN, Copeland TD Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem 1994, 269:2258-2262.
46. Van Vlierberghe P, van Grotel M, Tchinda J, et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood 2008, 111:4668-4680.
47. Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007, 117:2408-2421.
48. Christensen DJ, Chen Y, Oddo J, et al. SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood 2011, 118:4150-4158.
49. Xu P, Xu XL, Huang Q, Zhang ZH, Zhang YB CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis. Med Oncol 2012, 29:1643-1647.
50. Bockelman C, Lassus H, Hemmes A, et al. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer 2011, 105:989-995.
51. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 2012, 14:68.
52. Lin YC, Chen KC, Chen CC, Cheng AL, Chen KF CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncol 2012, 48:585-593.
53. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 2011, 117:6660-6668.
54. Cristobal I, Blanco FJ, Garcia-Orti L, et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 2010, 115:615-625.
55. Panagopoulos I, Kerndrup G, Carlsen N, Strombeck B, Isaksson M, Johansson B Fusion of NUP98 and the SET binding protein 1 (SETBP1) gene in a paediatric acute T cell lymphoblastic leukaemia with t(11;18)(p15;q12). Br J Haematol 2007, 136:294-296.
56. Mannava S, Omilian AR, Wawrzyniak JA, et al. PP2A-B56alpha controls oncogene-induced senescence in normal and tumor human melanocytic cells. Oncogene 2012, 31:1484-1492.
57. Sablina AA, Hector M, Colpaert N, Hahn WC Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res 2010, 70:10474-10484.
58. Ruediger R, Ruiz J, Walter G Human cancer-associated mutations in the Aalpha subunit of protein phosphatase 2A increase lung cancer incidence in Aalpha knock-in and knockout mice. Mol Cell Biol 2011, 31:3832-3844.
59. Li Y, Nie CJ, Hu L, et al. Characterization of a novel mechanism of genomic instability involving the SEI1/SET/NM23H1 pathway in esophageal cancers. Cancer Res 2010, 70:5695-5705.
60. Al-Murrani SW, Woodgett JR, Damuni Z Expression of I2PP2A, an inhibitor of protein phosphatase 2A, induces c-Jun and AP-1 activity. Biochem J 1999, 341:293-298.
61. Kandilci A, Grosveld GC SET-induced calcium signaling and MAPK/ERK pathway activation mediate dendritic cell-like differentiation of U937 cells. Leukemia 2005, 19:1439-1445.
62. Trotta R, Ciarlariello D, Dal Col J, et al. The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells. Blood 2011, 117:2378-2384.
63. Trotta R, Ciarlariello D, Dal Col J, et al. The PP2A inhibitor SET regulates natural killer cell IFN-gamma production. J Exp Med 2007, 204:2397-2405.
64. Oaks JJ, Mukhopadhyay A, Santhanam R, et al. FTY720 restores PP2A tumor suppressor activity in polycythemia vera CD34+ progenitors through inhibition of Jak2 V617F- and PI-3K{gamma}-dependent SET serine phosphorylation and enhancement of NOS-dependent PP2A tyrosine nitration. American Society of Hematology Annual Meeting and Exposition; San Diego, CA, USA; Dec 10-13, 2011. Abstract 2494.
65. Salas A, Ponnusamy S, Senkal CE, et al. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood 2011, 117:5941-5952.
66. Hu Z, Pan XF, Wu FQ, et al. Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS One 2009, 4:6257.
67. Pellicano F, Sinclair A, Holyoake TL In search of CML stem cells' deadly weakness. Curr Hematol Malig Rep 2011, 6:82-87.
68. Neviani P, Harb JG, Oaks JJ, et al. BCR-ABL1 kinase activity but not its expression is dispensable for Ph+ quiescent stem cell survival which depends on the PP2A-controlled Jak2 activation and is sensitive to FTY720 treatment. American Society of Hematology Annual Meeting and Exposition; Orlando, FL, USA; Dec 4-7, 2010. Abstract 515.
69. Ingwersen J, Aktas O, Kuery P, Kieseier B, Boyko A, Hartung HP Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin Immunol 2012, 142:15-24.
70. Kahan BD FTY720: from bench to bedside. Transplant Proc 2004, 36(suppl 2):531-543.
71. LaMontagne K, Littlewood-Evans A, Schnell C, et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 2006, 66:221-231.
72. Azuma H, Horie S, Muto S, et al. Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity. Anticancer Res 2003, 23:3183-3193.
73. Nagahara Y, Ikekita M, Shinomiya T T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2. Br J Pharmacol 2002, 137:953-962.
74. Yasui H, Hideshima T, Raje N, et al. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res 2005, 65:7478-7484.
75. Azuma H, Takahara S, Horie S, Muto S, Otsuki Y, Katsuoka Y Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol 2003, 169:2372-2377.
76. Chua CW, Lee DT, Ling MT, et al. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int J Cancer 2005, 117:1039-1048.
77. Nagaoka Y, Otsuki K, Fujita T, Uesato S Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells. Biol Pharm Bull 2008, 31:1177-1181.
78. Lee TK, Man K, Ho JW, et al. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res 2005, 11:8458-8466.
79. Lee TK, Man K, Ho JW, et al. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis 2004, 25:2397-2405.
80. Lim KG, Tonelli F, Li Z, et al. FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem 2011, 286:18633-18640.
81. Omar HA, Chou CC, Berman-Booty LD, et al. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology 2011, 53:1943-1958.
82. Walker C, Oaks JJ, Neviani P, et al. PP2A activating drugs (PAD): anti-leukemic and non-toxic activity of two novel and non-immunosuppressive FTY720 derivatives. American Society of Hematology Annual Meeting and Exposition; Orlando, FL, USA; Dec 4-7, 2010. Abstract 2901.
83. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011, 25:606-614.
84. Wallington-Beddoe CT, Hewson J, Bradstock KF, Bendall LJ FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. Autophagy 2011, 7:707-715.
85. Alinari L, Baiocchi RA, Praetorius-Ibba M FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment?. Autophagy 2012, 8:416-417.
86. Liao A, Broeg K, Fox T, et al. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood 2011, 118:2793-2800.
87. Shah MV, Zhang R, Irby R, et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 2008, 112:770-781.
88. Liu Q, Zhao X, Frissora F, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008, 111:275-284.
89. Agarwal A, MacKenzie R, Oddo J, Vitek MP, Christensen DJ, Druker BJ. A novel SET antagonist (OP449) is cytotoxic to CML cells, including the highly-resistant BCR-ABLT315I mutant, and demonstrates enhanced efficacy in combination with ABL tyrosine kinase inhibitors. American Society of Hematology Annual Meeting and Exposition; San Diego, CA, USA; Dec 10-13, 2011. Abstract 3757.
90. Christensen DJ, Ohkubo N, Oddo J, et al. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol 2011, 186:2535-2542.
91. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 2011, 30:2504-2513.
92. Guenin S, Schwartz L, Morvan D, et al. PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: a mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment. Int J Oncol 2008, 32:49-57.
93. Neuzil J, Weber T, Schroder A, et al. Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. Faseb J 2001, 15:403-415.
94. Park MA, Mitchell C, Zhang G, et al. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res 2010, 70:6313-6324.
95. Kar S, Palit S, Ball WB, Das PK Carnosic acid modulates Akt/IKK/NF-kappaB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells. Apoptosis 2012, 17:735-747.
96. Yuksel S, Saydam G, Uslu R, et al. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Leuk Res 2002, 26:391-398.
97. Kim SW, Kim HJ, Chun YJ, Kim MY Ceramide produces apoptosis through induction of p27(kip1) by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells. J Toxicol Environ Health A 2010, 73:1465-1476.
98. Sebestyen A, Hajdu M, Kis L, Barna G, Kopper L Smad4-independent, PP2A-dependent apoptotic effect of exogenous transforming growth factor beta 1 in lymphoma cells. Exp Cell Res 2007, 313:3167-3174.